193 related articles for article (PubMed ID: 34837101)
1. Metformin inhibits human non-small cell lung cancer by regulating AMPK-CEBPB-PDL1 signaling pathway.
Lu T; Li M; Zhao M; Huang Y; Bi G; Liang J; Chen Z; Zheng Y; Xi J; Lin Z; Zhan C; Jiang W; Wang Q; Tan L
Cancer Immunol Immunother; 2022 Jul; 71(7):1733-1746. PubMed ID: 34837101
[TBL] [Abstract][Full Text] [Related]
2. Baicalin, a Chinese Herbal Medicine, Inhibits the Proliferation and Migration of Human Non-Small Cell Lung Carcinoma (NSCLC) Cells, A549 and H1299, by Activating the SIRT1/AMPK Signaling Pathway.
You J; Cheng J; Yu B; Duan C; Peng J
Med Sci Monit; 2018 Apr; 24():2126-2133. PubMed ID: 29632297
[TBL] [Abstract][Full Text] [Related]
3. Nootkatone, an AMPK activator derived from grapefruit, inhibits KRAS downstream pathway and sensitizes non-small-cell lung cancer A549 cells to adriamycin.
Hung LVM; Moon JY; Ryu JY; Cho SK
Phytomedicine; 2019 Oct; 63():153000. PubMed ID: 31280139
[TBL] [Abstract][Full Text] [Related]
4. IL‑21/IL‑21R inhibit tumor growth and invasion in non‑small cell lung cancer cells via suppressing Wnt/β‑catenin signaling and PD‑L1 expression.
Xue D; Yang P; Wei Q; Li X; Lin L; Lin T
Int J Mol Med; 2019 Nov; 44(5):1697-1706. PubMed ID: 31573051
[TBL] [Abstract][Full Text] [Related]
5. Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines.
Maehara O; Ohnishi S; Asano A; Suda G; Natsuizaka M; Nakagawa K; Kobayashi M; Sakamoto N; Takeda H
Neoplasia; 2019 Jun; 21(6):545-556. PubMed ID: 31042624
[TBL] [Abstract][Full Text] [Related]
6. CCAAT enhancer binding protein-beta regulates matrix metalloproteinase-1 expression in interleukin-1beta-stimulated A549 lung carcinoma cells.
Armstrong DA; Phelps LN; Vincenti MP
Mol Cancer Res; 2009 Sep; 7(9):1517-24. PubMed ID: 19723873
[TBL] [Abstract][Full Text] [Related]
7. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
[TBL] [Abstract][Full Text] [Related]
8. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
[TBL] [Abstract][Full Text] [Related]
9. CEBPB is required for NRF2-mediated drug resistance in NRF2-activated non-small cell lung cancer cells.
Okazaki K; Anzawa H; Katsuoka F; Kinoshita K; Sekine H; Motohashi H
J Biochem; 2022 May; 171(5):567-578. PubMed ID: 35137113
[TBL] [Abstract][Full Text] [Related]
10. NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin.
Suwei D; Liang Z; Zhimin L; Ruilei L; Yingying Z; Zhen L; Chunlei G; Zhangchao L; Yuanbo X; Jinyan Y; Gaofeng L; Xin S
J Hematol Oncol; 2015 Oct; 8():120. PubMed ID: 26503334
[TBL] [Abstract][Full Text] [Related]
11. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
12. Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells.
Dong J; Peng H; Yang X; Wu W; Zhao Y; Chen D; Chen L; Liu J
Anticancer Drugs; 2020 Apr; 31(4):345-352. PubMed ID: 31789625
[TBL] [Abstract][Full Text] [Related]
13. Metformin Suppresses Stemness of Non-Small-Cell Lung Cancer Induced by Paclitaxel through FOXO3a.
Tang Z; Zhang Y; Yu Z; Luo Z
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068934
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells.
Salani B; Maffioli S; Hamoudane M; Parodi A; Ravera S; Passalacqua M; Alama A; Nhiri M; Cordera R; Maggi D
FASEB J; 2012 Feb; 26(2):788-98. PubMed ID: 22038047
[TBL] [Abstract][Full Text] [Related]
15. PDL1 Regulation by p53 via miR-34.
Cortez MA; Ivan C; Valdecanas D; Wang X; Peltier HJ; Ye Y; Araujo L; Carbone DP; Shilo K; Giri DK; Kelnar K; Martin D; Komaki R; Gomez DR; Krishnan S; Calin GA; Bader AG; Welsh JW
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26577528
[TBL] [Abstract][Full Text] [Related]
16. Downregulated Long Noncoding RNA GAS5 Fails to Function as Decoy of CEBPB, Resulting in Increased GDF15 Expression and Rapid Ovarian Cancer Cell Proliferation.
Guo LL; Wang SF
Cancer Biother Radiopharm; 2019 Oct; 34(8):537-546. PubMed ID: 31314588
[No Abstract] [Full Text] [Related]
17. Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth.
Hann SS; Tang Q; Zheng F; Zhao S; Chen J; Wang Z
Mol Cancer; 2014 Jun; 13():149. PubMed ID: 24925061
[TBL] [Abstract][Full Text] [Related]
18. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.
Storozhuk Y; Hopmans SN; Sanli T; Barron C; Tsiani E; Cutz JC; Pond G; Wright J; Singh G; Tsakiridis T
Br J Cancer; 2013 May; 108(10):2021-32. PubMed ID: 23632475
[TBL] [Abstract][Full Text] [Related]
19. Combination of the cuproptosis inducer disulfiram and anti‑PD‑L1 abolishes NSCLC resistance by ATP7B to regulate the HIF‑1 signaling pathway.
Li P; Sun Q; Bai S; Wang H; Zhao L
Int J Mol Med; 2024 Feb; 53(2):. PubMed ID: 38186308
[TBL] [Abstract][Full Text] [Related]
20. Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT process.
Li F; Zhu T; Yue Y; Zhu X; Wang J; Liang L
Oncol Rep; 2018 Aug; 40(2):775-782. PubMed ID: 29901173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
